{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-003500","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.034015+00:00","generated_at":"2026-06-04T10:27:16.670193+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Dermata Therapeutics reports FY 2023 net loss; cash runway into Q3 2024; Phase 3 acne trial underway","bullets":["Cash and equivalents $7.4M as of Dec 31, 2023 vs $6.2M in 2022; expects to fund ops into Q3 2024.","Net proceeds of $7.6M from three 2023 financings partially offset $6.4M cash used in operations.","R&D expenses $4.1M in 2023 (down from $5.7M in 2022) due to lower clinical costs offset by CMC for Phase 3.","Enrollment initiated in DMT310 Phase 3 STAR-1 acne trial in Q4 2023; topline results expected Q1 2025.","Japanese patent issued for DMT410 for hyperhidrosis; partnership discussions ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-003500","json":"https://secwatch.observer/filing/0001654954-24-003500.json","markdown":"https://secwatch.observer/filing/0001654954-24-003500.md","text":"https://secwatch.observer/filing/0001654954-24-003500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424003500/0001654954-24-003500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424003500/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:27:16.670193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af3c13315947315eca954f4c2456afc768f99c8d","claim":"Dermata Therapeutics, Inc. reported financial results for full year ended December 31, 2023.","evidence_excerpt":"On March 21, 2024, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424003500/0001654954-24-003500-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}